Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Satoru Takahashi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Evaluation of an AI-Assisted Diagnostic Support System for Early Gastric Cancer: Diagnostic Performance, Confidence Stratification, and Determinants of False-Positive Diagnosis

    by Satoshi Osawa, Takanori Yamada, Wataru Inui, Tomoyuki Niwa, Kenichi Takahashi, Takatoshi Egami, Keisuke Inagaki, Tomohiro Takebe, Tatsuhiro Ito, Satoru Takahashi, et al.

    Background/Objectives: Artificial intelligence (AI)-assisted endoscopy has shown high sensitivity for early gastric cancer detection; however, false-positive diagnoses remain a clinical challenge. This study aimed to evaluate the real-world diagnostic performance of a commercially available AI system and to identify factors associated with false-positive diagnoses, focusing on repeated AI evaluations and confidence stratification. Methods: This single-center retrospective study included 47 patients with 89 localized gastric lesions evaluated between March 2024 and March 2025. Endoscopic examinations were performed under white-light, non-magnified observation with repeated AI assessments of each lesion. The rates of “Consider biopsy” (B) judgments were calculated. Lesions with a B judgment rate of ≥50% were defined as AI-positive and classified into four AI confidence categories. Diagnostic performance was assessed using sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Factors associated with false-positive diagnoses were analyzed using penalized logistic regression. Results: The AI system demonstrated a sensitivity of 97.6% and an NPV of 95.7%, with a specificity of 45.8%. Pathology-positive rates decreased stepwise across the four AI confidence categories (p < 0.001). Among AI-positive lesions, low regional reproducibility, lesion size ≥ 30 mm, scar, and erosion were independently associated with false-positive diagnoses. In analyses restricted to non-neoplastic lesions, lesion size ≥ 30 mm remained significantly associated with false-positive diagnosis. Conclusions: In real-world clinical practice, a commercially available AI system provides high sensitivity for early gastric cancer detection. Incorporating confidence stratification and regional reproducibility into clinical decision-making may enhance the effective use of AI-assisted endoscopic diagnosis beyond binary interpretations.


  • Open Access

    Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori

    by Takahisa Furuta, Mihoko Yamade, Tomohiro Higuchi, Satoru Takahashi, Natsuki Ishida, Shinya Tani, Satoshi Tamura, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, et al.

    Vonoprazan (VPZ) inhibits gastric acid secretion more potently than proton pump inhibitors. Recently, attention has been focused on the dual therapy with VPZ and amoxicillin (AMOX) for the eradication of H. pylori. The dual VPZ/AMOX therapy attains the sufficient eradication rate with lowering the risk of adverse events in comparison with the triple therapy and quadruple therapy. Therefore, the dual VPZ/AMOX therapy is considered a useful eradication regimen for H. pylori infection.


  • Open Access

    Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis

    by Natsuki Ishida, Satoru Takahashi, Yusuke Asai, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, et al.

    Leukocyte subtypes can be used to evaluate the severity of ulcerative colitis (UC). In this study, we examined the relationship between the lymphocyte-to-monocyte ratio (LMR) and the Mayo endoscopic score (MES) in assessing endoscopic activity in UC. Eighty-nine samples of leukocyte subtypes and biomarkers, including fecal calprotectin (FC), the fecal immunochemical occult blood test (FIT), and C-reactive protein (CRP), from 71 patients with UC were retrospectively investigated, along with the MES. The MES was significantly correlated with the LMR, FC, the FIT, and CRP. There were significant differences in the LMR, FC, the FIT, and CRP between groups with an MES < 1 and >2 (p = 0.001, p = 0.003, p < 0.001, and p < 0.001, respectively). In the receiver operating characteristic (ROC) analysis for predicting mucosal healing (MES 0 or 1), the areas under the curve (AUCs) for the LMR, FC, the FIT, and CRP, were 0.712, 0.860, 0.908, and 0.796, respectively. In the analysis of patients without immunomodulators, the correlation of the MES with the LMR and CRP was significant. The LMR can be used to assess endoscopic activity in UC, particularly in patients without immunomodulators.